Effective January 1, 2023, David Liu, Protagonist Therapeutics, Inc.'s Chief R&D Strategy Officer, transitioned to a part-time R&D Strategy Advisor due to health reasons. In his new role, Dr. Liu is no longer a Section 16 or executive officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.15 USD | +1.59% | -7.43% | +22.76% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.76% | 1.63B | |
+43.36% | 58.06B | |
-5.31% | 40.53B | |
+37.52% | 38.99B | |
+14.75% | 26.7B | |
-12.56% | 26.56B | |
-22.45% | 18.98B | |
+0.04% | 12.17B | |
+25.12% | 12B | |
+26.04% | 11.92B |
- Stock Market
- Equities
- PTGX Stock
- News Protagonist Therapeutics, Inc.
- Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transitioned to Part-Time R&D Strategy Advisor